{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:11:14Z","timestamp":1780492274360,"version":"3.54.1"},"posted":{"date-parts":[[2025,10,14]]},"group-title":"In Review","reference-count":106,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,9,25]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  The endocannabinoid (eCB) system has been proposed as a potential target for developing new medications for opioid use disorder (OUD). However, the status of the eCB system, specifically brain cannabinoid receptor type 1 (CB1R) in OUD, is unknown. In this study, CB1R availability was measured in males with OUD on stable opioid agonist treatment (OAT) (n\u2009=\u200910) versus healthy controls (HC) (n\u2009=\u200918), using High-Resolution Research Tomography (HRRT) and the CB1R-specific radiotracer, [\n                  <sup>11<\/sup>\n                  C]OMAR. The average volume of distribution (\n                  <italic>V<\/italic>\n                  <sub>\n                    <italic>T<\/italic>\n                  <\/sub>\n                  ) across 13 regions was compared between the OUD and HC groups. Average\n                  <italic>V<\/italic>\n                  <sub>\n                    <italic>T<\/italic>\n                  <\/sub>\n                  was 15% lower in OUD vs. HC subjects (p\u2009=\u20090.04). Lower\n                  <italic>V<\/italic>\n                  <sub>\n                    <italic>T<\/italic>\n                  <\/sub>\n                  in OUD compared to HC was also observed in several corticolimbic areas. Within OUD no effects on CB1R availability were observed for treatment medication (methadone vs. buprenorphine), current stress levels, or antidepressant medication. No associations between the average\n                  <italic>V<\/italic>\n                  <sub>\n                    <italic>T<\/italic>\n                  <\/sub>\n                  and duration of OAT treatment or time since the last illicit opioid use were observed. This preliminary study suggests lower CB1R availability in men with OUD. Larger studies are necessary to replicate these findings. Future research should also draw from a more heterogeneous population, particularly by incorporating females, to better assess the potential confounding and moderating clinical factors. If confirmed, the observed alterations in CB1R availability in OUD may provide a rationale for targeting the eCB system in the treatment of OUD.\n                <\/p>","DOI":"10.21203\/rs.3.rs-7715611\/v1","type":"posted-content","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T11:50:11Z","timestamp":1760442611000},"source":"Crossref","is-referenced-by-count":0,"title":["A Preliminary Investigation of Brain Cannabinoid Receptor Type 1 (CB1R) Availability in Men with Opioid Use Disorder"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3890-3518","authenticated-orcid":false,"given":"ANAHITA BASSIR","family":"NIA","sequence":"first","affiliation":[{"name":"Yale University School of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ardavan Mohammad","family":"Aghaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8071-7412","authenticated-orcid":false,"given":"Jeremy","family":"Weleff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6772-7149","authenticated-orcid":false,"given":"Oluwole","family":"Jegede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Pittman","sequence":"additional","affiliation":[{"name":"Yale School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6066-9406","authenticated-orcid":false,"given":"Ilan","family":"Harpaz-Rotem","sequence":"additional","affiliation":[{"name":"Yale University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8105-1381","authenticated-orcid":false,"given":"Ansel","family":"Hillmer","sequence":"additional","affiliation":[{"name":"University of Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-1462","authenticated-orcid":false,"given":"Deepak","family":"D'Souza","sequence":"additional","affiliation":[{"name":"Yale University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"1. Wide-ranging online data for epidemiologic research (WONDER). Atlanta GC, National Center for Health Statistics; 2017. Available at http:\/\/wonder.cdc.gov."},{"key":"ref2","unstructured":"2. National Center for Health Statistics (2025): U.S. Overdose Deaths Decrease in 2023, First Time Since 2018. National Center for Health Statistics,."},{"key":"ref3","unstructured":"3. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality (2020): National Survey on Drug Use and Health 2019 (NSDUH-2019-DS0001)."},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"4. Kampman K, Jarvis M (2015): American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. J Addict Med. 9:358\u2013367.","DOI":"10.1097\/ADM.0000000000000166"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"5. (2020): The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. J Addict Med. 14:1\u201391.","DOI":"10.1097\/ADM.0000000000000633"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"6. Nosyk B, Marsh DC, Sun H, Schechter MT, Anis AH (2010): Trends in methadone maintenance treatment participation, retention, and compliance to dosing guidelines in British Columbia, Canada: 1996\u20132006. J Subst Abuse Treat. 39:22\u201331.","DOI":"10.1016\/j.jsat.2010.03.008"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"7. Lo A, Kerr T, Hayashi K, Milloy MJ, Nosova E, Liu Y, et al. (2018): Factors associated with methadone maintenance therapy discontinuation among people who inject drugs. J Subst Abuse Treat. 94:41\u201346.","DOI":"10.1016\/j.jsat.2018.08.009"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"8. Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, et al. (2014): Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial. Addiction. 109:79\u201387.","DOI":"10.1111\/add.12333"},{"key":"ref9","unstructured":"9. Smyth BP, Barry J, Keenan E, Ducray K (2010): Lapse and relapse following inpatient treatment of opiate dependence. Ir Med J. 103:176\u2013179."},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"10. Darker CD, Ho J, Kelly G, Whiston L, Barry J (2016): Demographic and clinical factors predicting retention in methadone maintenance: results from an Irish cohort. Ir J Med Sci. 185:433\u2013441.","DOI":"10.1007\/s11845-015-1314-5"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"11. Strain EC, Bigelow GE, Liebson IA, Stitzer ML (1999): Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA. 281:1000\u20131005.","DOI":"10.1001\/jama.281.11.1000"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"12. Calabria B, Degenhardt L, Briegleb C, Vos T, Hall W, Lynskey M, et al. (2010): Systematic review of prospective studies investigating \"remission\" from amphetamine, cannabis, cocaine or opioid dependence. Addict Behav. 35:741\u2013749.","DOI":"10.1016\/j.addbeh.2010.03.019"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"13. Vaillant GE (1973): A 20-year follow-up of New York narcotic addicts. Arch Gen Psychiatry. 29:237\u2013241.","DOI":"10.1001\/archpsyc.1973.04200020065009"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"14. Mart\u00ednez-Rivera A, Fetcho RN, Birmingham L, Xu J, Yang R, Foord C, et al. (2024): Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia. Sci Adv. 10:eadq4779.","DOI":"10.1126\/sciadv.adq4779"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"15. Wilkerson JL, Ghosh S, Mustafa M, Abdullah RA, Niphakis MJ, Cabrera R, et al. (2017): The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice. Neuropharmacology. 114:156\u2013167.","DOI":"10.1016\/j.neuropharm.2016.11.015"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"16. Oliva I, Kazi F, Cantwell LN, Thakur GA, Crystal JD, Hohmann AG (2024): Negative allosteric modulation of CB1 cannabinoid receptor signalling decreases intravenous morphine self-administration and relapse in mice. Addict Biol. 29:e13429.","DOI":"10.1111\/adb.13429"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"17. Iyer V, Saberi SA, Pacheco R, Sizemore EF, Stockman S, Kulkarni A, et al. (2024): Negative allosteric modulation of CB(1) cannabinoid receptor signaling suppresses opioid-mediated tolerance and withdrawal without blocking opioid antinociception. Neuropharmacology. 257:110052.","DOI":"10.1016\/j.neuropharm.2024.110052"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"18. Gamble MC, Miracle S, Williams BR, Logan RW (2024): Endocannabinoid agonist 2-arachidonoylglycerol differentially alters diurnal activity and sleep during fentanyl withdrawal in male and female mice. Pharmacol Biochem Behav. 240:173791.","DOI":"10.1016\/j.pbb.2024.173791"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"19. Scavone JL, Mackie K, Van Bockstaele EJ (2010): Characterization of cannabinoid-1 receptors in the locus coeruleus: relationship with mu-opioid receptors. Brain Res. 1312:18\u201331.","DOI":"10.1016\/j.brainres.2009.11.023"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"20. Rodriguez JJ, Mackie K, Pickel VM (2001): Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci. 21:823\u2013833.","DOI":"10.1523\/JNEUROSCI.21-03-00823.2001"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"21. Lopez-Moreno JA, Lopez-Jimenez A, Gorriti MA, de Fonseca FR (2010): Functional interactions between endogenous cannabinoid and opioid systems: focus on alcohol, genetics and drug-addicted behaviors. Curr Drug Targets. 11:406\u2013428.","DOI":"10.2174\/138945010790980312"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"22. Ahmad T, Lauzon NM, de Jaeger X, Laviolette SR (2013): Cannabinoid transmission in the prelimbic cortex bidirectionally controls opiate reward and aversion signaling through dissociable kappa versus mu-opiate receptor dependent mechanisms. J Neurosci. 33:15642\u201315651.","DOI":"10.1523\/JNEUROSCI.1686-13.2013"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"23. Wills KL, DeVuono MV, Limebeer CL, Vemuri K, Makriyannis A, Parker LA (2017): CB(1) receptor antagonism in the bed nucleus of the stria terminalis interferes with affective opioid withdrawal in rats. Behav Neurosci. 131:304\u2013311.","DOI":"10.1037\/bne0000201"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"24. Parolaro D, Rubino T, Vigano D, Massi P, Guidali C, Realini N (2010): Cellular mechanisms underlying the interaction between cannabinoid and opioid system. Curr Drug Targets. 11:393\u2013405.","DOI":"10.2174\/138945010790980367"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"25. Massi P, Vaccani A, Romorini S, Parolaro D (2001): Comparative characterization in the rat of the interaction between cannabinoids and opiates for their immunosuppressive and analgesic effects. J Neuroimmunol. 117:116\u2013124.","DOI":"10.1016\/S0165-5728(01)00323-X"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"26. Maldonado R, Valverde O (2003): Participation of the opioid system in cannabinoid-induced antinociception and emotional-like responses. Eur Neuropsychopharmacol. 13:401\u2013410.","DOI":"10.1016\/j.euroneuro.2003.08.001"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"27. Scavone JL, Sterling RC, Van Bockstaele EJ (2013): Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience. 248:637\u2013654.","DOI":"10.1016\/j.neuroscience.2013.04.034"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"28. Suzuki J, Weiss RD (2021): Cannabinoids for the Treatment of Opioid Use Disorder: Where is the Evidence? J Addict Med. 15:91\u201392.","DOI":"10.1097\/ADM.0000000000000711"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"29. Blessing E, Virani S, Rotrosen J (2020): Clinical Trials for Opioid Use Disorder. Handb Exp Pharmacol. 258:167\u2013202.","DOI":"10.1007\/164_2019_304"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"30. Gonzalez S, Schmid PC, Fernandez-Ruiz J, Krebsbach R, Schmid HH, Ramos JA (2003): Region-dependent changes in endocannabinoid transmission in the brain of morphine-dependent rats. Addict Biol. 8:159\u2013166.","DOI":"10.1080\/1355621031000117383"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"31. Li W, Zhang CL, Qiu ZG (2017): Differential expression of endocannabinoid system-related genes in the dorsal hippocampus following expression and reinstatement of morphine conditioned place preference in mice. Neurosci Lett. 643:38\u201344.","DOI":"10.1016\/j.neulet.2017.02.025"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"32. Gonzalez S, Fernandez-Ruiz J, Sparpaglione V, Parolaro D, Ramos JA (2002): Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB(1) receptor binding and mRNA levels. Drug Alcohol Depend. 66:77\u201384.","DOI":"10.1016\/S0376-8716(01)00186-7"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"33. Rubino T, Tizzoni L, Vigan\u00f2 D, Massi P, Parolaro D (1997): Modulation of rat brain cannabinoid receptors after chronic morphine treatment. Neuroreport. 8:3219\u20133223.","DOI":"10.1097\/00001756-199710200-00007"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"34. Vigano D, Grazia Cascio M, Rubino T, Fezza F, Vaccani A, Di Marzo V, et al. (2003): Chronic morphine modulates the contents of the endocannabinoid, 2-arachidonoyl glycerol, in rat brain. Neuropsychopharmacology. 28:1160\u20131167.","DOI":"10.1038\/sj.npp.1300117"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"35. Vigano D, Valenti M, Cascio MG, Di Marzo V, Parolaro D, Rubino T (2004): Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine. Eur J Neurosci. 20:1849\u20131857.","DOI":"10.1111\/j.1460-9568.2004.03645.x"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"36. Shyu C, Butler K, Tyndale RF, Smith A, Tardelli VS, Kloiber S, et al. (2024): Investigating Endocannabinoid Metabolism in Opioid Treated Chronic Pain Patients With and Without Opioid Use Disorder: A PET Study With Fatty Acid Amide Hydrolase Radioligand [C-11]CURB. Biological Psychiatry. 95:S113.","DOI":"10.1016\/j.biopsych.2024.02.270"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"37. Wong DF, Kuwabara H, Horti AG, Raymont V, Brasic J, Guevara M, et al. (2010): Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage. 52:1505\u20131513.","DOI":"10.1016\/j.neuroimage.2010.04.034"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"38. Normandin MD, Zheng MQ, Lin KS, Mason NS, Lin SF, Ropchan J, et al. (2015): Imaging the cannabinoid CB1 receptor in humans with [11C]OMAR: assessment of kinetic analysis methods, test-retest reproducibility, and gender differences. J Cereb Blood Flow Metab. 35:1313\u20131322.","DOI":"10.1038\/jcbfm.2015.46"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"39. Tsujikawa T, Zoghbi SS, Hong J, Donohue SR, Jenko KJ, Gladding RL, et al. (2014): In vitro and in vivo evaluation of (11)C-SD5024, a novel PET radioligand for human brain imaging of cannabinoid CB1 receptors. Neuroimage. 84:733\u2013741.","DOI":"10.1016\/j.neuroimage.2013.09.043"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"40. Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A, et al. (2013): Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry. 18:1034\u20131040.","DOI":"10.1038\/mp.2013.61"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"41. D'Souza DC, Cortes-Briones JA, Ranganathan M, Thurnauer H, Creatura G, Surti T, et al. (2016): Rapid Changes in CB1 Receptor Availability in Cannabis Dependent Males after Abstinence from Cannabis. Biol Psychiatry Cogn Neurosci Neuroimaging. 1:60\u201367.","DOI":"10.1016\/j.bpsc.2015.09.008"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"42. Ranganathan M, Cortes-Briones J, Radhakrishnan R, Thurnauer H, Planeta B, Skosnik P, et al. (2016): Reduced Brain Cannabinoid Receptor Availability in Schizophrenia. Biol Psychiatry. 79:997\u20131005.","DOI":"10.1016\/j.biopsych.2015.08.021"},{"key":"ref43","unstructured":"43. Boersma P, Villarroel MA, Vahratian A (2020): Heavy Drinking Among U.S. Adults, 2018. Centers for Disease Control and Prevention: Centers for Disease Control and Prevention."},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"44. Tarasi B, Cornuz J, Clair C, Baud D (2022): Cigarette smoking during pregnancy and adverse perinatal outcomes: a cross-sectional study over 10 years. BMC Public Health. 22:2403.","DOI":"10.1186\/s12889-022-14881-4"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"45. Pierce JP, Messer K, White MM, Cowling DW, Thomas DP (2011): Prevalence of heavy smoking in California and the United States, 1965\u20132007. Jama. 305:1106\u20131112.","DOI":"10.1001\/jama.2011.334"},{"key":"ref46","unstructured":"46. Horti AG, Fan H, Kuwabara H, Hilton J, Ravert HT, Holt DP, et al. (2006): 11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. J Nucl Med. 47:1689\u20131696."},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"47. Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF (2000): Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol. 27:627\u2013630.","DOI":"10.1016\/S0969-8051(00)00125-6"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"48. Carson RE, Barker WC, Liow J-S, Johnson CA (2003): Design of a motion-compensation OSEM list-mode algorithm for resolution-recovery reconstruction for the HRRT. Nuclear Science Symposium Conference Record, 2003 IEEE: IEEE, pp 3281\u20133285.","DOI":"10.1109\/NSSMIC.2003.1352597"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"49. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. (2002): Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 15:273\u2013289.","DOI":"10.1006\/nimg.2001.0978"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"50. Lin HC, Wang PW, Wu HC, Ko CH, Yang YH, Yen CF (2018): Altered gray matter volume and disrupted functional connectivity of dorsolateral prefrontal cortex in men with heroin dependence. Psychiatry Clin Neurosci. 72:435\u2013444.","DOI":"10.1111\/pcn.12655"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"51. Schmidt A, Vogel M, Baumgartner S, Wiesbeck GA, Lang U, Borgwardt S, et al. (2021): Brain volume changes after long-term injectable opioid treatment: A longitudinal voxel-based morphometry study. Addict Biol. 26:e12970.","DOI":"10.1111\/adb.12970"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"52. Shi H, Liang Z, Chen J, Li W, Zhu J, Li Y, et al. (2020): Gray matter alteration in heroin-dependent men: An atlas-based magnetic resonance imaging study. Psychiatry Res Neuroimaging. 304:111150.","DOI":"10.1016\/j.pscychresns.2020.111150"},{"key":"ref53","unstructured":"53. Giovacchini G, Lerner A, Toczek MT, Fraser C, Ma K, DeMar JC, et al. (2004): Brain Incorporation of 11C-Arachidonic Acid, Blood Volume, and Blood Flow in Healthy Aging: A Study With Partial-Volume Correction. Journal of Nuclear Medicine. 45:1471\u20131479."},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"54. Hillmer AT, Sandiego CM, Hannestad J, Angarita GA, Kumar A, McGovern EM, et al. (2017): In vivo imaging of translocator protein, a marker of activated microglia, in alcohol dependence. Mol Psychiatry. 22:1759\u20131766.","DOI":"10.1038\/mp.2017.10"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"55. Hillmer AT, Angarita GA, Esterlis I, Anderson JM, Nabulsi N, Lim K, et al. (2021): Longitudinal imaging of metabotropic glutamate 5 receptors during early and extended alcohol abstinence. Neuropsychopharmacology. 46:380\u2013385.","DOI":"10.1038\/s41386-020-00856-9"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"56. Ichise M, Toyama H, Innis RB, Carson RE (2002): Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab. 22:1271\u20131281.","DOI":"10.1097\/01.WCB.0000038000.34930.4E"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"57. Mayo LM, Asratian A, Lind\u00e9 J, Morena M, Haataja R, Hammar V, et al. (2020): Elevated Anandamide, Enhanced Recall of Fear Extinction, and Attenuated Stress Responses Following Inhibition of Fatty Acid Amide Hydrolase: A Randomized, Controlled Experimental Medicine Trial. Biological Psychiatry. 87:538\u2013547.","DOI":"10.1016\/j.biopsych.2019.07.034"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"58. Valverde O, Noble F, Beslot F, Dauge V, Fournie-Zaluski MC, Roques BP (2001): Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur J Neurosci. 13:1816\u20131824.","DOI":"10.1046\/j.0953-816x.2001.01558.x"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"59. Koch M, Varela L, Kim JG, Kim JD, Hernandez-Nuno F, Simonds SE, et al. (2015): Hypothalamic POMC neurons promote cannabinoid-induced feeding. Nature. 519:45\u201350.","DOI":"10.1038\/nature14260"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"60. Molaei M, Fatahi Z, Zaringhalam J, Haghparast A (2016): CB1 Cannabinoid Agonist (WIN55,212-2) Within the Basolateral Amygdala Induced Sensitization to Morphine and Increased the Level of mu-Opioid Receptor and c-fos in the Nucleus Accumbens. J Mol Neurosci. 58:446\u2013455.","DOI":"10.1007\/s12031-016-0716-9"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"61. Fattore L, Vigano D, Fadda P, Rubino T, Fratta W, Parolaro D (2007): Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-administering heroin or WIN 55,212-2. Eur J Neurosci. 25:2191\u20132200.","DOI":"10.1111\/j.1460-9568.2007.05470.x"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"62. Caille S, Alvarez-Jaimes L, Polis I, Stouffer DG, Parsons LH (2007): Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. J Neurosci. 27:3695\u20133702.","DOI":"10.1523\/JNEUROSCI.4403-06.2007"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"63. Sustkova-Fiserova M, Charalambous C, Havlickova T, Lapka M, Jerabek P, Puskina N, et al. (2017): Alterations in Rat Accumbens Endocannabinoid and GABA Content during Fentanyl Treatment: The Role of Ghrelin. Int J Mol Sci. 18.","DOI":"10.3390\/ijms18112486"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"64. Zhang J, Wang N, Chen B, Wang Y, He J, Cai X, et al. (2016): Blockade of Cannabinoid CB1 receptor attenuates the acquisition of morphine-induced conditioned place preference along with a downregulation of ERK, CREB phosphorylation, and BDNF expression in the nucleus accumbens and hippocampus. Neurosci Lett. 630:70\u201376.","DOI":"10.1016\/j.neulet.2016.07.047"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"65. Jin L, Pan L, Guo Y, Zheng Y, Nie Z, Zhu R (2014): Expression and localization of cannabinoid receptor 1 in rats' brain treated with acute and repeated morphine. Acta Neurobiol Exp (Wars). 74:288\u2013297.","DOI":"10.55782\/ane-2014-1994"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"66. Wiese B, Wilson-Poe AR (2018): Emerging Evidence for Cannabis' Role in Opioid Use Disorder. Cannabis Cannabinoid Res. 3:179\u2013189.","DOI":"10.1089\/can.2018.0022"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"67. Chye Y, Christensen E, Solowij N, Yucel M (2019): The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder. Front Psychiatry. 10:63.","DOI":"10.3389\/fpsyt.2019.00063"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"68. Sloan ME, Gowin JL, Ramchandani VA, Hurd YL, Le Foll B (2017): The endocannabinoid system as a target for addiction treatment: Trials and tribulations. Neuropharmacology. 124:73\u201383.","DOI":"10.1016\/j.neuropharm.2017.05.031"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"69. Solinas M, Panlilio LV, Tanda G, Makriyannis A, Matthews SA, Goldberg SR (2005): Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology. 30:2046\u20132057.","DOI":"10.1038\/sj.npp.1300754"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"70. Lichtman AH, Sheikh SM, Loh HH, Martin BR (2001): Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther. 298:1007\u20131014.","DOI":"10.1016\/S0022-3565(24)29469-6"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"71. Yamaguchi T, Hagiwara Y, Tanaka H, Sugiura T, Waku K, Shoyama Y, et al. (2001): Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice. Brain Res. 909:121\u2013126.","DOI":"10.1016\/S0006-8993(01)02655-5"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"72. Lofwall MR, Babalonis S, Nuzzo PA, Elayi SC, Walsh SL (2016): Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans. Drug Alcohol Depend. 164:143\u2013150.","DOI":"10.1016\/j.drugalcdep.2016.05.002"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"73. Hurd YL, Spriggs S, Alishayev J, Winkel G, Gurgov K, Kudrich C, et al. (2019): Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial. Am J Psychiatry. 176:911\u2013922.","DOI":"10.1176\/appi.ajp.2019.18101191"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"74. Degenhardt L, Lintzeris N, Campbell G, Bruno R, Cohen M, Farrell M, et al. (2015): Experience of adjunctive cannabis use for chronic non-cancer pain: findings from the Pain and Opioids IN Treatment (POINT) study. Drug Alcohol Depend. 147:144\u2013150.","DOI":"10.1016\/j.drugalcdep.2014.11.031"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"75. Campbell G, Hall WD, Peacock A, Lintzeris N, Bruno R, Larance B, et al. (2018): Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Health. 3:e341-e350.","DOI":"10.1016\/S2468-2667(18)30110-5"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"76. Boehnke KF, Litinas E, Clauw DJ (2016): Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain. J Pain. 17:739\u2013744.","DOI":"10.1016\/j.jpain.2016.03.002"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"77. Haroutounian S, Ratz Y, Ginosar Y, Furmanov K, Saifi F, Meidan R, et al. (2016): The Effect of Medicinal Cannabis on Pain and Quality-of-Life Outcomes in Chronic Pain: A Prospective Open-label Study. Clin J Pain. 32:1036\u20131043.","DOI":"10.1097\/AJP.0000000000000364"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"78. Kral AH, Wenger L, Novak SP, Chu D, Corsi KF, Coffa D, et al. (2015): Is cannabis use associated with less opioid use among people who inject drugs? Drug Alcohol Depend. 153:236\u2013241.","DOI":"10.1016\/j.drugalcdep.2015.05.014"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"79. Bellnier T, Brown GW, Ortega TR (2018): Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis. Ment Health Clin. 8:110\u2013115.","DOI":"10.9740\/mhc.2018.05.110"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"80. Goggin MM, Shahriar BJ, Stead A, Janis GC (2019): Reduced urinary opioid levels from pain management patients associated with marijuana use. Pain Manag. 9:441\u2013447.","DOI":"10.2217\/pmt-2019-0017"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"81. Vigil JM, Stith SS, Adams IM, Reeve AP (2017): Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study. PLoS One. 12:e0187795.","DOI":"10.1371\/journal.pone.0187795"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"82. El-Mourad J, Lunghi C, Herrera NP, Zongo A (2024): Dosing of cannabinoids associated with an opioid-sparing effect: a systematic review of longitudinal studies. Pain Management Nursing. 25:e8-e20.","DOI":"10.1016\/j.pmn.2023.08.005"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"83. Nielsen S, Picco L, Murnion B, Winters B, Matheson J, Graham M, et al. (2022): Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies. Neuropsychopharmacology. 47:1315\u20131330.","DOI":"10.1038\/s41386-022-01322-4"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"84. Costa GPA, Nunes JC, Heringer DL, Anand A, De Aquino JP (2024): The impact of cannabis on non-medical opioid use among individuals receiving pharmacotherapies for opioid use disorder: a systematic review and meta-analysis of longitudinal studies. Am J Drug Alcohol Abuse. 50:12\u201326.","DOI":"10.1080\/00952990.2023.2287406"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"85. Mayo LM, Asratian A, Lind\u00e9 J, Morena M, Haataja R, Hammar V, et al. (2020): Elevated Anandamide, Enhanced Recall of Fear Extinction, and Attenuated Stress Responses Following Inhibition of Fatty Acid Amide Hydrolase: A Randomized, Controlled Experimental Medicine Trial. Biol Psychiatry. 87:538\u2013547.","DOI":"10.1016\/j.biopsych.2019.07.034"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"86. D'Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E, et al. (2019): Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. Lancet Psychiatry. 6:35\u201345.","DOI":"10.1016\/S2215-0366(18)30427-9"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"87. Melis M, Pillolla G, Luchicchi A, Muntoni AL, Yasar S, Goldberg SR, et al. (2008): Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. J Neurosci. 28:13985\u201313994.","DOI":"10.1523\/JNEUROSCI.3221-08.2008"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"88. Panlilio LV, Justinova Z, Goldberg SR (2013): Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction. Pharmacol Ther. 138:84\u2013102.","DOI":"10.1016\/j.pharmthera.2013.01.003"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"89. Miliano C, Natividad LA, Quello S, Stoolmiller M, Gregus AM, Buczynski MW, et al. (2024): The Predictive Value of Plasma Bioactive Lipids on Craving in Human Volunteers With Alcohol Use Disorder. Biol Psychiatry Glob Open Sci. 4:100368.","DOI":"10.1016\/j.bpsgos.2024.100368"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"90. Boachie N, Gaudette E, Bazinet RP, Lin L, Tyndale RF, Mansouri E, et al. (2023): Circulating Endocannabinoids and N-Acylethanolamines in Individuals with Cannabis Use Disorder-Preliminary Findings. Brain Sci. 13.","DOI":"10.3390\/brainsci13101375"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"91. Voegel CD, Kroll SL, Schmid MW, Kexel AK, Baumgartner MR, Kraemer T, et al. (2022): Alterations of Stress-Related Glucocorticoids and Endocannabinoids in Hair of Chronic Cocaine Users. Int J Neuropsychopharmacol. 25:226\u2013237.","DOI":"10.1093\/ijnp\/pyab070"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"92. Mitra S, Gobira PH, Werner CT, Martin JA, Iida M, Thomas SA, et al. (2021): A role for the endocannabinoid enzymes monoacylglycerol and diacylglycerol lipases in cue-induced cocaine craving following prolonged abstinence. Addict Biol. 26:e13007.","DOI":"10.1111\/adb.13007"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"93. Parsons LH, Hurd YL (2015): Endocannabinoid signalling in reward and addiction. Nat Rev Neurosci. 16:579\u2013594.","DOI":"10.1038\/nrn4004"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"94. Solinas M, Goldberg SR, Piomelli D (2008): The endocannabinoid system in brain reward processes. Br J Pharmacol. 154:369\u2013383.","DOI":"10.1038\/bjp.2008.130"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"95. Hirvonen J, Zanotti-Fregonara P, Umhau JC, George DT, Rallis-Frutos D, Lyoo CH, et al. (2013): Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography. Mol Psychiatry. 18:916\u2013921.","DOI":"10.1038\/mp.2012.100"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"96. Hirvonen J, Zanotti-Fregonara P, Gorelick DA, Lyoo CH, Rallis-Frutos D, Morse C, et al. (2018): Decreased Cannabinoid CB(1) Receptors in Male Tobacco Smokers Examined With Positron Emission Tomography. Biol Psychiatry. 84:715\u2013721.","DOI":"10.1016\/j.biopsych.2018.07.009"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"97. Farquhar CE, Breivogel CS, Gamage TF, Gay EA, Thomas BF, Craft RM, et al. (2019): Sex, THC, and hormones: Effects on density and sensitivity of CB1 cannabinoid receptors in rats. Drug and alcohol dependence. 194:20\u201327.","DOI":"10.1016\/j.drugalcdep.2018.09.018"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"98. Liu X, Li X, Zhao G, Wang F, Wang L (2020): Sexual dimorphic distribution of cannabinoid 1 receptor mRNA in adult C57BL\/6J mice. Journal of Comparative Neurology. 528:1986\u20131999.","DOI":"10.1002\/cne.24868"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"99. Llorente-Berzal A, Assis MA, Rubino T, Zamberletti E, Marco EM, Parolaro D, et al. (2013): Sex-dependent changes in brain CB1R expression and functionality and immune CB2R expression as a consequence of maternal deprivation and adolescent cocaine exposure. Pharmacological research. 74:23\u201333.","DOI":"10.1016\/j.phrs.2013.05.001"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"100. Paola Castelli M, Fadda P, Casu A, Sabrina Spano M, Casti A, Fratta W, et al. (2014): Male and female rats differ in brain cannabinoid CB1 receptor density and function and in behavioural traits predisposing to drug addiction: effect of ovarian hormones. Current pharmaceutical design. 20:2100\u20132113.","DOI":"10.2174\/13816128113199990430"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"101. Craft RM, Wakley AA, Tsutsui KT, Laggart JD (2012): Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by \u22069-tetrahydrocannabinol and CP55, 940 in the rat. Journal of Pharmacology and Experimental Therapeutics. 340:787\u2013800.","DOI":"10.1124\/jpet.111.188540"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"102. Van Laere K, Goffin K, Casteels C, Dupont P, Mortelmans L, de Hoon J, et al. (2008): Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [18F] MK-9470 PET. Neuroimage. 39:1533\u20131541.","DOI":"10.1016\/j.neuroimage.2007.10.053"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"103. Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng M-Q, Gujarro-Anton A, et al. (2013): Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Molecular psychiatry. 18:1034\u20131040.","DOI":"10.1038\/mp.2013.61"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"104. Normandin MD, Zheng M-Q, Lin K-S, Mason NS, Lin S-F, Ropchan J, et al. (2015): Imaging the cannabinoid cb1 receptor in humans with [11c] omar: assessment of kinetic analysis methods, test\u2013retest reproducibility, and gender differences. Journal of Cerebral Blood Flow & Metabolism. 35:1313\u20131322.","DOI":"10.1038\/jcbfm.2015.46"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"105. Laurikainen H, Tuominen L, Tikka M, Merisaari H, Armio R-L, Sormunen E, et al. (2019): Sex difference in brain CB1 receptor availability in man. Neuroimage. 184:834\u2013842.","DOI":"10.1016\/j.neuroimage.2018.10.013"},{"key":"ref106","doi-asserted-by":"crossref","unstructured":"106. Radhakrishnan R, Worhunsky PD, Zheng M-Q, Najafzadeh S, Gallezot J-D, Planeta B, et al. (2022): Age, gender and body-mass-index relationships with in vivo CB1 receptor availability in healthy humans measured with [11C] OMAR PET. NeuroImage. 264:119674.","DOI":"10.1016\/j.neuroimage.2022.119674"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7715611\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7715611\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:36:18Z","timestamp":1780490178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7715611\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":106,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-7715611\/v1","relation":{},"subject":[],"published":{"date-parts":[[2025,10,14]]},"subtype":"preprint"}}